In response to carbapenem resistance, cefepime combined with tanibobactam achieves positive results

Pharmaceutical company Venatorx today announced positive results from a Phase III study (CERTAIN-1 trial) investigating the efficacy and safety of cefepime in combination with taniborbactam in the treatment of complicated urinary tract infections

CERTAIN-1 enrolled 661 adult patients with cUTIs, including acute pyelonephritis, who were randomly assigned to receive cefepime plus taniborbactam or meropenem for 1 week or up to 2 weeks if they had bacteremia

Venatorx said the combination of cefepime and taniborbactam met the primary efficacy endpoint of being statistically noninferior to meropenem, with composite microbiological and clinical success occurring in 70% of patients in the experimental treatment arm compared to 58% of patients in the meropenem arm

Cefepime, a fourth-generation cephalosporin, is a widely used beta-lactam antibiotic against Gram-negative and Gram-positive bacteria; taniborbactam, also known as VNRX-5133, is a novel Broad-spectrum beta-lactamase inhibitor

Original source:

https://firstwordpharma.